Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma (original) (raw)

Abstract

An analysis of survival time of 57 West European patients with hepatocellular carcinoma was carried out to define which of several possible factors (age, sex, cirrhosis and raised serum alpha-foetoprotein (AFP)) influenced survival. Although survival was significantly longer in younger patients (P less than 0.02) and in patients with normal serum AFP (P less than 0.01), multivariate analysis showed that significant variation in survival time is better explained by the single factor, the presence of cirrhosis, than by AFP level. This does not seem to apply for patients with this tumour in Africa and the Far East, and there may be a fundamental difference in the natural history of the tumour between high- and low-incidence areas.

502

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Johnson P. J., Portmann B., Williams R. Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J. 1978 Sep 2;2(6138):661–663. doi: 10.1136/bmj.2.6138.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Johnson P. J., Williams R., Thomas H., Sherlock S., Murray-Lyon I. M. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet. 1978 May 13;1(8072):1006–1009. doi: 10.1016/s0140-6736(78)90735-3. [DOI] [PubMed] [Google Scholar]
  3. Kohn J., Weaver P. C. Serum-alpha 1-fetoprotein in hepatocellular carcinoma. Lancet. 1974 Aug 10;2(7876):334–336. doi: 10.1016/s0140-6736(74)91705-x. [DOI] [PubMed] [Google Scholar]
  4. MacSween R. N. A clinicopathological review of 100 cases of primary malignant tumours of the liver. J Clin Pathol. 1974 Aug;27(8):669–682. doi: 10.1136/jcp.27.8.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Primack A., Vogel C. L., Kyalwazi S. K., Ziegler J. L., Simon R., Anthony P. P. A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients. Cancer. 1975 May;35(5):1357–1364. doi: 10.1002/1097-0142(197505)35:5<1357::aid-cncr2820350518>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. Provan J. L., Stokes J. F., Edwards D. Hepatic artery infusion chemotherapy in hepatoma. Br Med J. 1968 Aug 10;3(5614):346–349. doi: 10.1136/bmj.3.5614.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Purves L. R., Macnab M., Bersohn I. Serum alpha-feto-protein. I. Immunodiffusion and immuno-assay results in cases of primary cancer of the liver. S Afr Med J. 1968 Nov 2;42(42):1138–1141. [PubMed] [Google Scholar]
  8. Ruoslahti E., Seppälä M., Vuopio P., Saksela E., Peltokallio P. [Radioimmunoassay of alpha-fetoprotein in primary and secondary cancer of the liver]. J Natl Cancer Inst. 1972 Sep;49(3):623–630. [PubMed] [Google Scholar]
  9. Vogel C. L., Primack A., McIntire K. R., Carbone P. P., Anthony P. P. Serum alpha-fetoprotein in 184 Ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations. Cancer. 1974 Apr;33(4):959–964. doi: 10.1002/1097-0142(197404)33:4<959::aid-cncr2820330410>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]